ChromaDex® Acquires Pterostilbene Patent Rights

IRVINE, Calif.ChromaDex Corporation® (CDXC) gained patent rights from Green Molecular S.L. for pTeroPure® pterostilbene used in skin care applications.

The company will offer pharmaceutical and cosmetic preparations of pterostilbene for prevention and treatment of skin diseases, damage or injuries, including those relating to aging and sun exposure.

According to Mintel research, the U.S. market for skincare will reach almost $5 billion in 2013, with expected continued growth due to demand for anti-aging products. Companies are seeking innovative skincare solutions for their customers that are backed by science and protected by intellectual property, according to ChromaDex.

"We intend to continue our strategy to build intellectual property around our ingredients," said Frank Jaksch, founder and CEO of ChromaDex. "By building a robust skincare IP portfolio, we are positioning to become a meaningful provider of patent-protected innovative ingredient technologies to this growing multi-billion dollar marketplace."

ChromaDex's branded form of pterostilbene, pTeroPure®, is an antioxidant found in blueberries. In September 2012, the company announced findings that showed pTeroPure significantly reduced blood pressure in adults. Pterostilbene may also support heart health, cognitive function, anti-aging, weight loss and other metabolic disorders.